NMN trial raises blood NAD⁺ without significant hearing or physical-function gains

A randomized study published September 25 in npj Aging found that nicotinamide mononucleotide, or NMN, increased blood NAD⁺ concentrations without significantly improving hearing or physical performance. The result matters because a measurable biochemical response can be mistaken for evidence that an intervention preserves healthy aging.

### What the trial reported

The double-blind, placebo-controlled trial studied healthy adults aged 65 and older over 24 weeks. Hearing was the primary endpoint. Apparent changes in body composition, lipid-related measures and dietary behavior did not survive adjustment for multiple comparisons.

The authors described supplementation as generally well tolerated while calling for careful safety monitoring. MIRAILAB BIOSCIENCE funded the research and supplied NMN; three authors disclosed employment with the company.

### Why the blood measurement needs context

Separate research published May 14 in Nature Metabolism helps explain why blood NAD⁺ warrants cautious interpretation. Investigators used a validated analytical method to examine seven independent human cohorts. Whole-blood NAD⁺ remained broadly stable across age and the lifestyle interventions examined, although it responded to supplementation with nicotinamide riboside, a different NAD⁺ precursor.

Those researchers questioned the usefulness of blood NAD⁺ as a marker of aging or lifestyle factors. Their findings concern whole blood; they do not establish that NAD⁺ behaves identically in every tissue. Nor was that study a replication of the newly published NMN trial.

Read together, the papers support a distinction between changing a laboratory measurement and demonstrating a meaningful health outcome. A responsive blood marker can help researchers establish that an intervention affects the measured pathway. It still needs validation before it can stand in for better hearing, mobility, disease prevention or longer survival.

### How to interpret an unsuccessful endpoint

A primary endpoint gives a trial a defined question against which success is assessed. Other measurements can generate useful hypotheses, but their interpretation becomes more difficult when investigators examine many outcomes. Some apparently favorable differences can emerge by chance simply because there were numerous opportunities to find them.

Statistical adjustment addresses that problem. An exploratory signal that does not survive the adjustment remains a question for another study; it should not be promoted into an established benefit.

Conversely, a nonsignificant result does not prove that the true effect is exactly zero. The precision of the estimate, sample size and variability all matter. The appropriate conclusion is limited to what the experiment establishes, rather than a universal verdict covering every population or possible use.

### What would strengthen the evidence

For healthspan research, the next evidentiary step is a reproducible improvement in an outcome people experience: preserved function, fewer illnesses or sustained independence. Stronger studies would specify those outcomes in advance, enroll enough participants to estimate clinically meaningful differences and follow them long enough to assess durability.

Safety requires its own evidence. Short-term tolerability cannot establish the absence of uncommon harms or consequences that emerge after prolonged exposure. Independent replication also becomes especially valuable when a product supplier supports the research.

For readers evaluating longevity claims, the practical question is therefore what improved, how it was measured and whether the improvement translated into daily life. A laboratory response alone cannot answer all three.